
  
    
      
        Introduction_NNP
        In_IN addition_NN to_TO the_DT role_NN of_IN smoking_NN in_IN cancer_NN initiation_NN and_CC promotion_NN ,_, cigarette_NN smoking_NN
        accelerates_VBZ atherogenic_JJ cardiovascular_JJ disease_NN in_IN both_DT a_DT dose-_NN and_CC a_DT duration-dependent_JJ
        manner_NN through_IN several_JJ concurrent_JJ pathways_NNS ._. Smoking_NN incites_NNS an_DT immunologic_JJ response_NN to_TO
        vascular_NN injury_NN ,_, described_VBD as_IN oxidative_JJ stress_NN leading_VBG to_TO lipid_NN peroxidation_NN ,_, endothelial_NN
        cell_NN dysfunction_NN ,_, and_CC foam_NN cell_NN proliferation_NN in_IN the_DT tunica_NN media_NNS [_NN 1_CD ,_, 2_CD ]_NN ._. Smoking_NN also_RB
        enhances_VBZ platelet_NN aggregation_NN ,_, impairs_NNS lipoprotein_NN metabolism_NN ,_, depresses_VBZ high-density_JJ
        lipoprotein_NN (_( HDL_NNP )_) cholesterol_NN ,_, and_CC reduces_VBZ distensibility_NN of_IN vessel_NN walls_NNS [_NN 3_CD ,_, 4_CD ]_NN ._.
        Cigarette_NNP smoking_NN is_VBZ associated_VBN with_IN increased_VBN levels_NNS of_IN inflammatory_JJ markers_NNS ._. During_IN
        the_DT acute_JJ phase_NN of_IN inflammatory_JJ states_NNS ,_, there_EX are_VBP quantifiable_JJ increases_NNS in_IN C-_NNP reactive_JJ
        protein_NN ,_, white_JJ blood_NN cell_NN count_NN ,_, and_CC fibrinogen_NN ,_, and_CC decreases_NNS in_IN serum_NN albumin_NN [_NN 5_CD –_NN 8_CD ]_NN ._.
        Acute_NNP inflammatory_JJ markers_NNS have_VBP been_VBN shown_VBN to_TO be_VB both_DT prognostic_JJ and_CC predictive_JJ of_IN future_JJ
        cardiovascular_JJ events_NNS in_IN several_JJ populations_NNS ._. For_IN example_NN ,_, C-_NNP reactive_JJ protein_NN has_VBZ been_VBN
        discussed_VBN extensively_RB as_IN a_DT marker_NN of_IN cardiovascular_JJ disease_NN risk_NN [_NN 9_CD –_NN 16_CD ]_NN ._.
        C-_NNP reactive_JJ protein_NN in_IN particular_NN is_VBZ also_RB increasingly_RB being_VBG implicated_VBN in_IN the_DT
        pathogenesis_NNS of_IN atherosclerosis_NNS [_NN 17_CD –_NN 19_CD ]_NN ._. C-_NNP reactive_JJ protein_NN is_VBZ a_DT pentaxin_NN ,_, highly_RB conserved_JJ
        across_IN species_NNS [_NN 17_CD ,_, 20_CD ,_, 21_CD ]_NN and_CC stimulated_VBN synergistically_RB by_IN both_DT IL-_NNP 6_CD and_CC IL-_NNP 1_CD β_NN [_NN 22_CD –_NN 25_CD ]_NN ._.
        Previously_RB believed_VBN to_TO be_VB synthesized_JJ by_IN the_DT liver_NN ,_, recent_JJ evidence_NN suggests_VBZ that_IN
        C-_NNP reactive_JJ protein_NN is_VBZ also_RB produced_VBN at_IN the_DT site_NN of_IN atherosclerosis_NNS by_IN smooth_JJ muscle_NN cells_NNS
        [_NN 17_CD ]_NN ._. In_IN the_DT vessel_NN wall_NN ,_, it_PRP induces_VBZ expression_NN of_IN adhesion_NN molecules_NNS on_IN endothelial_NN cells_NNS
        and_CC increases_NNS monocyte_NN chemotactic_JJ protein-_NN 1_CD ,_, which_WDT attracts_VBZ monocytes_NNS and_CC T_NN cells_NNS into_IN the_DT
        vessel_NN wall_NN [_NN 26_CD –_NN 28_CD ]_NN ._. Additionally_RB ,_, C-_NNP reactive_JJ protein_NN reduces_VBZ endothelial_NN nitric_JJ oxide_NN
        synthase_NN ,_, upregulates_NNS the_DT proatherosclerotic_JJ NF-κB_NNP pathway_NN ,_, enhances_VBZ low-density_NN
        lipoprotein_NN (_( LDL_NNP )_) uptake_NN by_IN macrophages_NNS ,_, which_WDT become_VBP foam_NN cells_NNS ,_, and_CC facilitates_NNS T-_NNP cell-_NN
        and_CC complement-mediated_JJ destruction_NN and_CC apoptosis_NNS of_IN the_DT endothelium_NN [_NN 2_CD ,_, 26_CD ,_, 29_CD –_NN 31_CD ]_NN ._. Thus_RB ,_,
        C-_NNP reactive_JJ protein_NN is_VBZ increasingly_RB described_VBN not_RB only_RB as_IN a_DT marker_NN of_IN the_DT inflammatory_JJ
        response_NN ,_, but_CC also_RB as_IN a_DT mediator_NN in_IN the_DT pathogenesis_NNS of_IN atherosclerotic_JJ cardiovascular_JJ
        disease_NN [_NN 2_CD ,_, 27_CD ]_NN ._. Other_JJ inflammatory_JJ markers_NNS may_MD also_RB have_VB causal_NN properties_NNS ,_, but_CC are_VBP not_RB as_RB
        well_RB understood_VBN ._. The_DT inflammatory_JJ response_NN therefore_RB not_RB only_RB indicates_VBZ atherosclerotic_JJ
        potential_NN ,_, but_CC may_MD accelerate_VB atherosclerosis_NNS ._.
        Several_JJ studies_NNS have_VBP described_VBN a_DT prevalent_JJ inflammatory_JJ state_NN in_IN smokers_NNS ._. Despite_IN the_DT
        known_VBN impact_NN of_IN smoking_NN on_IN cardiovascular_JJ disease_NN progression_NN ,_, few_JJ studies_NNS have_VBP examined_VBN
        the_DT impact_NN of_IN smoking_NN cessation_NN on_IN levels_NNS of_IN inflammatory_JJ markers_NNS or_CC on_IN cardiovascular_JJ risk_NN
        reduction_NN [_NN 6_CD ,_, 32_CD ]_NN ._. The_DT level_NN to_TO which_WDT the_DT inflammatory_JJ response_NN subsides_NNS following_VBG smoking_NN
        cessation_NN and_CC the_DT rate_NN at_IN which_WDT the_DT inflammatory_JJ response_NN subsides_NNS are_VBP uncertain_JJ ._.
        Furthermore_RB ,_, it_PRP remains_VBZ unclear_JJ whether_IN traditional_JJ risk_NN factors_NNS can_MD adequately_RB explain_VB the_DT
        decline_NN in_IN cardiovascular_JJ risk_NN following_VBG smoking_NN cessation_NN ._.
        Using_VBG the_DT Third_NNP National_NNP Health_NNP and_CC Nutrition_NNP Examination_NNP Survey_NNP (_( NHANES_NNP III_NNP )_) ,_, a_DT
        population-based_JJ representative_NN sample_NN of_IN United_NNP States_NNPS adults_NNS ,_, we_PRP investigated_VBD the_DT
        association_NN between_IN smoking_NN and_CC smoking_NN cessation_NN and_CC levels_NNS of_IN inflammatory_JJ markers_NNS and_CC
        traditional_JJ cardiovascular_JJ risk_NN factors_NNS ._. We_PRP examined_VBD the_DT association_NN between_IN changes_NNS in_IN the_DT
        inflammatory_JJ markers—_NN C-_NNP reactive_JJ protein_NN ,_, white_JJ blood_NN cell_NN count_NN ,_, albumin_NN ,_, and_CC
        fibrinogen—and_NN the_DT traditional_JJ risk_NN factors—total_NN cholesterol_NN ,_, HDL_NNP cholesterol_NN ,_,
        triglycerides_NNS ,_, systolic_JJ blood_NN pressure_NN ,_, and_CC diabetes—with_NN decreased_VBD smoking_VBG intensity_NN and_CC
        increased_VBN time_NN since_IN smoking_NN cessation_NN ._. Our_PRP$ primary_JJ objective_NN was_VBD to_TO investigate_VB changes_NNS in_IN
        C-_NNP reactive_JJ protein_NN in_IN an_DT effort_NN to_TO characterize_VB the_DT excess_JJ cardiovascular_JJ risk_NN associated_VBN
        with_IN smoking_NN and_CC any_DT associated_VBN decline_NN in_IN risk_NN with_IN smoking_NN cessation_NN ._. We_PRP also_RB aimed_VBD to_TO
        characterize_VB whether_IN the_DT inflammatory_JJ markers_NNS or_CC traditional_JJ risk_NN factors_NNS explained_VBD
        observed_VBN cardiac_JJ risk_NN reduction_NN following_VBG smoking_NN cessation_NN ._.
      
      
        Methods_NNP
        
          Study_NNP Population_NNP
          The_DT NHANES_NNP III_NNP survey_NN and_CC data_NNS collection_NN procedures_NNS have_VBP been_VBN described_VBN in_IN detail_NN
          elsewhere_RB [_NN 33_CD ,_, 34_CD ]_NN ._. Briefly_NNP ,_, NHANES_NNP III_NNP was_VBD a_DT national_JJ probability_NN survey_NN conducted_VBN
          between_IN 1988_CD and_CC 1994_CD ._. This_DT survey_NN used_VBD a_DT complex_JJ ,_, multi-stage_JJ ,_, stratified_JJ cluster_NN
          sampling_VBG design_NN to_TO obtain_VB a_DT representative_NN sample_NN of_IN the_DT non-institutionalized_JJ civilian_JJ
          United_NNP States_NNPS population_NN ._. Participation_NNP included_VBD a_DT home_NN examination_NN and_CC a_DT visit_NN to_TO a_DT
          mobile_JJ examination_NN center_NN in_IN one_CD of_IN 89_CD locations_NNS ._. For_IN those_DT unable_JJ to_TO travel_VB to_TO a_DT mobile_JJ
          examination_NN center_NN ,_, a_DT special_JJ home_NN visit_NN was_VBD arranged_VBN ._.
          Of_IN the_DT 19_CD ,_, 618_CD persons_NNS aged_VBN 18_CD and_CC over_IN included_VBN in_IN the_DT NHANES_NNP III_NNP population_NN ,_, we_PRP
          excluded_VBD 3_CD ,_, 021_CD persons_NNS for_IN whom_WP C-_NNP reactive_JJ protein_NN levels_NNS were_VBD missing_VBG ,_, given_VBN that_IN this_DT
          was_VBD our_PRP$ primary_JJ marker_NN of_IN interest_NN ._. Another_DT 292_CD persons_NNS were_VBD excluded_VBN because_IN they_PRP were_VBD
          pregnant_JJ ,_, and_CC 816_CD people_NNS were_VBD excluded_VBN because_IN they_PRP reported_VBD cigar_NN ,_, pipe_NN ,_, snuff_NN ,_, or_CC
          chewing_VBG tobacco_NN use_NN ._. Data_NNS for_IN 15_CD ,_, 489_CD persons_NNS were_VBD analyzed_VBN ._.
        
        
          Measures_NNS
          Self-reported_NNP race_NN /_NN ethnicity_NN was_VBD categorized_VBN as_IN non-_NN Hispanic_JJ white_NN ,_, non-_NN Hispanic_JJ
          black_NN ,_, Mexican-_NNP American_NNP ,_, or_CC other_JJ ._. The_DT self-reported_JJ poverty_NN to_TO income_NN ratio_NN ,_, a_DT marker_NN of_IN
          socioeconomic_JJ status_NN used_VBN in_IN multiple_JJ prior_RB studies_VBZ [_NN 35_CD ,_, 36_CD ]_NN ,_, was_VBD classified_VBN as_IN <_NN 1_CD ._. 5_LS ,_,
          1_CD ._. 5_CD –_NN 3_CD ,_, or_CC >_NN 3_CD ._.
          Self-reported_NNP clinical_JJ factors_NNS were_VBD dichotomized_JJ for_IN analysis_NN ._. Participants_NNS reported_VBD
          on_IN use_NN of_IN non-steroidal_JJ anti-inflammatory_JJ drugs_NNS ,_, estrogen_NN replacement_NN therapy_NN ,_, and_CC
          vitamin_NN supplements_NNS ._. Use_NN of_IN any_DT alcohol_NN in_IN the_DT past_JJ 24_CD h_NN was_VBD measured_VBN by_IN dietary_JJ recall_NN
          questionnaire_NN ._. Prior_RB physician-diagnosed_JJ angina_NN ,_, myocardial_NN infarction_NN ,_, or_CC stroke_NN was_VBD
          defined_VBN as_IN prevalent_JJ atherosclerotic_JJ cardiovascular_JJ disease_NN (_( ASCVD_NNP )_) ._. Prevalent_NNP
          inflammatory_JJ disease_NN was_VBD defined_VBN as_IN the_DT presence_NN of_IN rheumatoid_NN arthritis_NN ,_, asthma_NN ,_,
          emphysema_NN ,_, or_CC chronic_JJ bronchitis_NNS ._. Presence_NNP of_IN acute_JJ illness_NN was_VBD indicated_VBN by_IN a_DT positive_JJ
          answer_NN to_TO the_DT question_NN :_: “ In_IN the_DT past_JJ few_JJ days_NNS have_VBP you_PRP had_VBD a_DT cough_NN ,_, cold_JJ ,_, or_CC other_JJ acute_JJ
          illness_NN ?_.”
          Additional_JJ clinical_JJ factors_NNS were_VBD measured_VBN by_IN a_DT combination_NN of_IN participant_NN self-report_JJ
          and_CC clinical_JJ exam_NN and_CC were_VBD also_RB dichotomized_JJ for_IN analysis_NN ._. Hypertension_NNP was_VBD indicated_VBN by_IN
          use_NN of_IN anti-hypertensive_JJ medication_NN ,_, an_DT average_JJ systolic_JJ blood_NN pressure_NN over_IN 140_CD mm_NN Hg_NNP ,_,
          or_CC an_DT average_JJ diastolic_JJ blood_NN pressure_NN over_IN 90_CD mm_NN Hg_NNP ,_, over_IN four_CD readings_NNS ._. Diabetes_NNP
          mellitus_JJ was_VBD considered_VBN present_JJ if_IN the_DT participant_NN reported_VBD physician_NN diagnosis_NN of_IN
          diabetes_NN mellitus_JJ (_( excluding_VBG diagnosis_NN during_IN pregnancy_NN )_) ,_, was_VBD taking_VBG diabetes_NN
          medications_NNS ,_, had_VBD fasting_VBG plasma_NN glucose_NN over_IN 7_CD mmol_NN /_NN l_NN (_( 126_CD mg_NN /_NN dl_NN )_) ,_, or_CC had_VBD non-fasting_JJ
          glucose_NN levels_NNS over_IN 11_CD ._. 1_LS mmol_NN /_NN l_NN (_( 200_CD mg_NN /_NN dl_NN )_) ._. Finally_RB ,_, serum_NN cholesterol_NN and_CC triglyceride_NN
          levels_NNS were_VBD measured_VBN enzymatically_RB (_( Hitachi_NNP 704_CD analyzer_NN ,_, Boehringer_NNP Mannheim_NNP ,_, Mannheim_NNP ,_,
          Germany_NNP )_) ._. LDL_NNP was_VBD calculated_VBN using_VBG the_DT Friedewald_NNP equation_NN and_CC measured_VBN fasting_VBG
          triglycerides_NNS ,_, total_JJ cholesterol_NN ,_, and_CC HDL_NNP cholesterol_NN ._. LDL_NNP cholesterol_NN and_CC triglycerides_NNS
          were_VBD included_VBN as_IN continuous_JJ variables_NNS and_CC were_VBD logarithmically_RB transformed_VBN to_TO approximate_JJ
          the_DT normal_JJ curve_NN ._.
          Smoking_NN history_NN was_VBD categorized_VBN based_VBN on_IN both_DT self-report_JJ and_CC serum_NN cotinine_NN levels_NNS ._.
          Persons_NNP who_WP gave_VBD a_DT history_NN of_IN current_JJ smoking_NN and_CC /_NN or_CC had_VBD serum_NN cotinine_NN levels_NNS greater_JJR
          than_IN 56_CD ._. 8_CD nmol_NN /_NN l_NN (_( 10_CD ng_NN /_NN ml_NN )_) were_VBD considered_VBN current_JJ smokers_NNS ._. Current_JJ smokers_NNS were_VBD
          categorized_VBN into_IN four_CD roughly_RB equal_JJ groups_NNS ,_, based_VBN on_IN number_NN of_IN cigarettes_NNS per_IN day_NN :_: 1_CD –_NN 9_CD ,_,
          10_CD –_NN 19_CD ,_, 20_CD –_NN 29_CD ,_, and_CC over_IN 30_CD cigarettes_NNS per_IN day_NN ._. Former_JJ smokers_NNS were_VBD defined_VBN by_IN self-report_JJ
          as_IN having_VBG smoked_VBD over_IN 100_CD cigarettes_NNS in_IN their_PRP$ lifetime_NN and_CC as_IN having_VBG quit_VBN smoking_VBG ._. Former_JJ
          smokers_NNS were_VBD categorized_VBN by_IN years_NNS since_IN smoking_NN cessation_NN ._. Since_IN the_DT zero_CD year_NN since_IN
          cessation_NN point_NN is_VBZ subject_JJ to_TO misclassification_NN bias_NN ,_, the_DT following_VBG levels_NNS were_VBD used_VBN in_IN
          analyses_NNS :_: <_NN 1_CD ,_, 1_CD –_NN 3_CD ,_, 3_CD –_NN 5_CD ,_, 5_CD –_NN 7_CD ,_, 7_CD –_NN 9_CD ,_, and_CC >_NN 9_CD ysince_NN cessation_NN ._. Never_RB smokers_NNS were_VBD
          defined_VBN by_IN self-report_JJ and_CC as_IN having_VBG serum_NN cotinine_NN levels_NNS under_IN 56_CD ._. 8_CD nmol_NN /_NN l_NN (_( <_NN 10_CD
          ng_NN /_NN ml_NN )_) ._. Passive_NNP smokers_NNS with_IN cotinine_NN levels_NNS over_IN 56_CD ._. 8_CD nmol_NN /_NN l_NN (_( 10_CD ng_NN /_NN ml_NN )_) were_VBD categorized_VBN
          as_IN smokers_NNS at_IN the_DT lowest_JJS dose-intensity_JJ level_NN ._.
          Our_PRP$ main_JJ outcome_NN variable_JJ ,_, C-_NNP reactive_JJ protein_NN ,_, was_VBD measured_VBN using_VBG a_DT latex-enhanced_JJ
          Behring_NNP Nephelometer_NNP Analyzer_NNP System_NNP (_( Dade_NNP Behring_NNP ,_, Deerfield_NNP ,_, Illinois_NNP ,_, United_NNP States_NNPS )_) ._.
          Because_IN the_DT presence_NN or_CC absence_NN ,_, rather_RB than_IN the_DT absolute_JJ level_NN ,_, of_IN C-_NNP reactive_JJ protein_NN
          appears_VBZ to_TO be_VB associated_VBN with_IN cardiovascular_JJ risk_NN ,_, we_PRP compared_VBD undetectable_JJ versus_CC
          detectable_JJ levels_NNS of_IN this_DT marker_NN ._. This_DT is_VBZ consistent_JJ with_IN previous_JJ research_NN ,_, given_VBN the_DT
          nonlinearity_NN of_IN C-_NNP reactive_JJ protein_NN interpretation_NN [_NN 37_CD ,_, 38_CD ]_NN ._. Since_IN the_DT limit_NN of_IN detection_NN
          for_IN the_DT latex-enhanced_JJ nephelometry_NN assay_NN was_VBD 2_CD ._. 1_CD mg_NN /_NN l_NN ,_, we_PRP defined_VBD undetectable_JJ as_IN less_JJR
          than_IN 2_CD ._. 1_CD mg_NN /_NN l_NN ._. Other_JJ outcome_NN variables_NNS were_VBD treated_VBN continuously_RB ._. White_JJ blood_NN cell_NN count_NN
          was_VBD determined_VBN using_VBG a_DT fully_RB automated_VBN Coulter_NNP S-PLUS_NNP JR_NNP hematology_NN analyzer_NN (_( Beckman_NNP
          Coulter_NNP ,_, Fullerton_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) ._. Albumin_NNP was_VBD measured_VBN using_VBG the_DT
          bromocresol_NN purple_JJ method_NN ._. Fibrinogen_NNP was_VBD measured_VBN using_VBG a_DT quantitative_JJ assay_NN of_IN clotting_VBG
          time_NN compared_VBN to_TO a_DT known_VBN standard_JJ ._.
        
        
          Statistical_NNP Methods_NNP
          The_DT distributions_NNS of_IN traditional_JJ risk_NN factors_NNS ,_, inflammatory_JJ markers_NNS ,_, and_CC clinical_JJ and_CC
          sociodemographic_JJ factors_NNS were_VBD examined_VBN by_IN smoking_VBG status_NN ._. Chi-square_NNP and_CC analysis_NN of_IN
          variance_NN tests_NNS ,_, as_IN appropriate_JJ ,_, were_VBD performed_VBN to_TO test_VB for_IN statistically_RB significant_JJ
          differences_NNS ._. Variables_NNP identified_VBD as_IN potential_JJ confounders_NNS by_IN these_DT bivariate_NN analyses_NNS
          were_VBD included_VBN in_IN multivariate_NN models_NNS ,_, as_IN were_VBD the_DT cofactors_NNS believed_VBN to_TO be_VB clinically_RB
          relevant_JJ ._.
          For_IN multivariate_NN analyses_NNS ,_, our_PRP$ primary_JJ independent_JJ variables_NNS were_VBD smoking_VBG intensity_NN
          and_CC time_NN since_IN smoking_NN cessation_NN ._. Our_PRP$ primary_JJ dependent_JJ variables_NNS were_VBD the_DT inflammatory_JJ
          markers—_NN C-_NNP reactive_JJ protein_NN ,_, fibrinogen_NN ,_, white_JJ blood_NN cell_NN count_NN ,_, and_CC serum_NN albumin—and_NN the_DT
          traditional_JJ risk_NN factors—systolic_JJ blood_NN pressure_NN ,_, total_JJ cholesterol_NN ,_, triglycerides_NNS ,_, HDL_NNP ,_,
          LDL_NNP ,_, diabetes_NN ,_, and_CC alcohol_NN use_NN ._. Two_CD sets_NNS of_IN multivariate_NN models_NNS were_VBD developed_VBN ._. The_DT first_JJ
          set_NN of_IN analyses_NNS (_( minimally_RB adjusted_VBN )_) were_VBD adjusted_VBN for_IN age_NN ,_, sex_NN ,_, and_CC race_NN ,_, given_VBN
          previously_RB reported_VBD differences_NNS in_IN the_DT distribution_NN of_IN inflammatory_JJ markers_NNS in_IN those_DT
          groups_NNS ._. The_DT second_RB set_NN of_IN analyses_NNS (_( fully_RB adjusted_VBN )_) were_VBD adjusted_VBN for_IN all_DT covariates_NNS and_CC
          potential_JJ confounders_NNS :_: age_NN ,_, sex_NN ,_, race_NN ,_, poverty_NN to_TO income_NN ratio_NN ,_, body_NN mass_NN index_NN ,_,
          prevalent_JJ cardiovascular_JJ disease_NN ,_, prevalent_JJ diabetes_NN ,_, prevalent_JJ chronic_JJ inflammatory_JJ
          condition_NN ,_, current_JJ acute_JJ illness_NN ,_, and_CC use_NN of_IN alcohol_NN ,_, non-steroidal_JJ anti-inflammatory_JJ
          medication_NN ,_, aspirin_NN ,_, and_CC estrogen_NN replacement_NN ._.
          For_IN inflammatory_JJ markers_NNS and_CC traditional_JJ risk_NN factors_NNS that_WDT were_VBD measured_VBN continuously_RB ,_,
          linear_JJ regressions_NNS were_VBD used_VBN to_TO model_VB the_DT relationship_NN to_TO smoking_NN intensity_NN and_CC time_NN
          since_IN smoking_NN cessation_NN ._. Least_NNP square_JJ means_NNS were_VBD calculated_VBN ._. C-_NNP reactive_JJ protein_NN (_( a_DT
          dichotomous_JJ variable_JJ )_) was_VBD modeled_VBN with_IN logistic_JJ regression_NN ,_, using_VBG never_RB smokers_NNS as_IN the_DT
          reference_NN category_NN ._. Odds_NNS ratios_NNS ,_, however_RB ,_, do_VBP not_RB approximate_JJ risk_NN ratios_NNS ,_, given_VBN that_IN the_DT
          prevalence_NN of_IN elevated_VBD C-_NNP reactive_JJ protein_NN is_VBZ over_IN 10_CD %_NN ._.
          The_DT dose–response_NN relationship_NN between_IN both_DT smoking_NN intensity_NN and_CC time_NN since_IN smoking_NN
          cessation_NN and_CC each_DT of_IN the_DT outcomes_NNS was_VBD assessed_VBN using_VBG Mantel_NNP tests_NNS for_IN trend_NN ._. Three_CD sets_NNS
          of_IN tests_NNS were_VBD performed_VBN ,_, evaluating_VBG the_DT trends_NNS :_: (_( 1_LS )_) among_IN current_JJ smokers_NNS by_IN cigarettes_NNS
          per_IN day_NN ;_: (_( 2_LS )_) among_IN former_JJ smokers_NNS by_IN time_NN since_IN cessation_NN ;_: and_CC (_( 3_LS )_) among_IN smokers_NNS ,_, former_JJ
          smokers_NNS ,_, and_CC non-smokers_JJ ,_, despite_IN the_DT potential_JJ nonlinearity_NN between_IN groups_NNS ._. To_TO further_VB
          explain_VB the_DT relationship_NN between_IN smoking_NN exposure_NN and_CC C-_NNP reactive_JJ protein_NN ,_, to_TO increase_VB the_DT
          power_NN to_TO detect_VB a_DT trend_NN ,_, and_CC to_TO reduce_VB residual_JJ confounding_VBG ,_, C-_NNP reactive_JJ protein_NN was_VBD
          categorized_VBN into_IN three_CD levels_NNS :_: under_IN 2_CD ._. 1_CD mg_NN /_NN l_NN (_( undetectable_JJ )_) ,_, 2_CD ._. 1_CD –_NN 9_CD ._. 9_CD mg_NN /_NN l_NN (_( mildly_RB
          elevated_VBD )_) ,_, and_CC ≥_NN 10_CD ._. 0_CD mg_NN /_NN l_NN (_( clinically_RB significant_JJ )_) ._.
          Lastly_NNP ,_, blocked_VBN group_NN comparisons_NNS were_VBD done_VBN using_VBG adjusted_VBN chi-square_JJ tests_NNS ._.
          Inflammatory_NNP and_CC traditional_JJ risk_NN factors_NNS were_VBD compared_VBN across_IN current_JJ ,_, former_JJ ,_, and_CC never_RB
          smokers_NNS to_TO validate_NN findings_NNS from_IN previous_JJ studies_NNS ._.
          All_DT analyses_NNS were_VBD weighted_VBN to_TO represent_VB the_DT total_JJ civilian_JJ ,_, non-institutionalized_JJ
          United_NNP States_NNPS population_NN ;_: they_PRP are_VBP ,_, therefore_RB ,_, population_NN prevalence_NN estimates_NNS ._. Analyses_NNS
          were_VBD conducted_VBN in_IN SAS_NNP (_( version_NN 8_CD ._. 02_CD ;_: SAS_NNP Institute_NNP ,_, Cary_NNP ,_, North_NNP Carolina_NNP ,_, United_NNP States_NNPS )_)
          and_CC SUDAAN_NNP (_( version_NN 9_CD ._. 0_CD ;_: Research_NNP Triangle_NNP Institute_NNP ,_, Research_NNP Triangle_NNP Park_NNP ,_, North_NNP ,_,
          Carolina_NNP ,_, United_NNP States_NNPS )_) ,_, incorporating_VBG sampling_VBG weights_NNS to_TO account_VB for_IN nonresponse_NN and_CC
          oversampling_VBG ._. All_DT analyses_NNS were_VBD conducted_VBN using_VBG two-sided_JJ tests_NNS with_IN alpha_NN set_VBN to_TO
          0_CD ._. 05_CD ._.
        
      
      
        Results_NNS
        Of_IN the_DT 15_CD ,_, 489_CD persons_NNS in_IN our_PRP$ sample_NN ,_, 7_CD ,_, 665_CD were_VBD classified_VBN as_RB never_RB smokers_NNS ,_, 3_CD ,_, 459_CD were_VBD
        classified_VBN as_IN former_JJ smokers_NNS ,_, and_CC 4_CD ,_, 365_CD were_VBD classified_VBN as_IN current_JJ smokers_NNS ._. The_DT average_JJ
        time_NN since_IN smoking_NN cessation_NN for_IN former_JJ smokers_NNS was_VBD 13_CD y_NN ._. The_DT average_JJ cotinine_NN level_NN for_IN
        current_JJ smokers_NNS was_VBD 1_CD ,_, 255_CD nmol_NN /_NN l_NN (_( 221_CD ng_NN /_NN ml_NN )_) ;_: for_IN both_DT former_JJ and_CC never_RB smokers_NNS the_DT average_JJ
        cotinine_NN level_NN was_VBD <_NN 3_CD nmol_NN /_NN l_NN (_( <_NN 0_CD ._. 5_LS ng_NN /_NN ml_NN )_) ._. Weighted_NNP descriptive_JJ statistics_NNS are_VBP given_VBN
        in_IN Table_NNP 1_CD ._.
        Bivariate_NNP analyses_NNS of_IN smoking_NN status_NN showed_VBD that_IN among_IN the_DT inflammatory_JJ risk_NN factors_NNS ,_,
        unadjusted_JJ C-_NNP reactive_JJ protein_NN ,_, white_JJ blood_NN cell_NN count_NN ,_, and_CC fibrinogen_NN were_VBD all_DT
        significantly_RB and_CC positively_RB associated_VBN with_IN smoking_NN status_NN (_(
        p_NN <_NN 0_CD ._. 01_CD )_) ._. Albumin_NNP levels_NNS were_VBD similar_JJ across_IN smoking_NN categories_NNS ._.
        Among_IN traditional_JJ risk_NN factors_NNS ,_, smokers_NNS had_VBD higher_JJR total_JJ cholesterol_NN and_CC triglycerides_NNS ,_, but_CC
        were_VBD otherwise_RB younger_JJR ,_, had_VBD lower_JJR body_NN mass_NN index_NN ,_, and_CC had_VBD lower_JJR blood_NN pressure_NN ,_, and_CC a_DT
        smaller_JJR proportion_NN were_VBD diabetic_JJ ._. Former_JJ smokers_NNS were_VBD most_RBS likely_JJ to_TO have_VB prevalent_JJ
        atherosclerotic_JJ cardiovascular_JJ disease_NN ._.
        Bivariate_NNP analyses_NNS of_IN the_DT inflammatory_JJ markers_NNS showed_VBD that_IN C-_NNP reactive_JJ protein_NN was_VBD
        significantly_RB associated_VBN with_IN older_JJR age_NN (_(
        p-_NN trend_NN <_NN 0_CD ._. 01_CD by_IN 10_CD -_: y_NN age_NN group_NN )_) ,_, female_JJ sex_NN (_(
        p_NN <_NN 0_CD ._. 01_CD )_) ,_, and_CC black_JJ race_NN (_(
        p_NN <_NN 0_CD ._. 01_CD )_) ._. Serum_NNP albumin_NN and_CC serum_NN fibrinogen_NN showed_VBD similarly_RB
        significant_JJ associations_NNS ._. White_JJ cell_NN count_NN was_VBD associated_VBN with_IN race_NN (_(
        p_NN <_NN 0_CD ._. 01_CD )_) ,_, but_CC not_RB with_IN age_NN or_CC sex_NN ._. Among_IN traditional_JJ risk_NN factors_NNS ,_,
        analyses_NNS showed_VBD that_IN total_JJ cholesterol_NN ,_, triglycerides_NNS ,_, HDL_NNP cholesterol_NN ,_, LDL_NNP cholesterol_NN ,_,
        and_CC systolic_JJ blood_NN pressure_NN were_VBD each_DT associated_VBN with_IN age_NN ,_, sex_NN ,_, and_CC race_NN (_( all_DT 
        p_NN <_NN 0_CD ._. 01_CD )_) ._. Diabetes_NNP was_VBD associated_VBN with_IN age_NN and_CC race_NN only_RB (_(
        p_NN <_NN 0_CD ._. 01_CD )_) ._. Alcohol_NN use_NN was_VBD associated_VBN with_IN age_NN and_CC sex_NN only_RB (_(
        p_NN <_NN 0_CD ._. 01_CD )_) ._. All_DT models_NNS ,_, therefore_RB ,_, were_VBD adjusted_VBN for_IN age_NN ,_, race_NN ,_, and_CC
        sex_NN ._.
        Table_NNP 2_CD displays_NNS abatement_NN of_IN the_DT inflammatory_JJ response_NN with_IN (_( 1_LS )_) reduced_VBN intensity_NN of_IN
        smoking_NN and_CC (_( 2_LS )_) increased_VBN time_NN since_IN smoking_NN cessation_NN ,_, adjusted_VBN for_IN age_NN ,_, sex_NN ,_, and_CC race_NN ._.
        C-_NNP reactive_JJ protein_NN ,_, white_JJ blood_NN cell_NN count_NN ,_, and_CC fibrinogen_NN were_VBD all_DT positively_RB associated_VBN
        with_IN increased_VBN smoking_NN intensity_NN (_(
        p_NN ≤_NN 0_CD ._. 01_CD )_) and_CC were_VBD all_DT significantly_RB negatively_RB associated_VBN with_IN time_NN
        since_IN smoking_NN cessation_NN (_(
        p_NN <_NN 0_CD ._. 05_CD )_) ._. Similarly_RB ,_, albumin_NN showed_VBD a_DT negative_JJ association_NN with_IN
        intensity_NN of_IN smoking_NN (_(
        p_NN ≤_NN 0_CD ._. 01_CD )_) ,_, but_CC no_DT relationship_NN after_IN cessation_NN ._. All_DT acute_JJ phase_NN reactant_NN
        inflammatory_JJ markers_NNS had_VBD significant_JJ trends_NNS overall_JJ ,_, from_IN current_JJ to_TO former_JJ to_TO never_RB
        smokers_NNS (_(
        p_NN ≤_NN 0_CD ._. 01_CD )_) (_( Figure_NN 1_LS )_) ._.
        Differences_NNS in_IN the_DT traditional_JJ cardiovascular_JJ risk_NN factors_NNS are_VBP shown_VBN in_IN Table_NNP 3_CD ,_,
        adjusted_VBN for_IN age_NN ,_, sex_NN ,_, and_CC race_NN ._. Total_JJ and_CC HDL_NNP cholesterol_NN ,_, triglycerides_NNS ,_, alcohol_NN usage_NN ,_,
        and_CC systolic_JJ blood_NN pressure_NN all_DT showed_VBD a_DT dose-dependent_JJ association_NN with_IN smoking_NN intensity_NN
        (_(
        p_NN <_NN 0_CD ._. 05_CD )_) ._. Triglycerides_NNP and_CC alcohol_NN use_NN showed_VBD time-dependent_JJ
        associations_NNS with_IN smoking_NN cessation_NN (_(
        p_NN ≤_NN 0_CD ._. 01_CD )_) ._. Overall_RB trends_NNS (_( from_IN current_JJ to_TO former_JJ to_TO never_RB smokers_NNS )_) were_VBD
        present_JJ for_IN alcohol_NN use_NN ,_, triglycerides_NNS ,_, total_JJ cholesterol_NN ,_, and_CC HDL_NNP cholesterol_NN ,_, as_IN shown_VBN in_IN
        Figure_NN 2_CD ._. In_IN models_NNS fully_RB adjusted_VBN for_IN all_DT covariates_NNS (_( not_RB shown_VBN )_) ,_, dose-dependent_JJ
        associations_NNS persisted_VBD for_IN HDL_NNP cholesterol_NN and_CC triglycerides_NNS (_(
        p_NN ≤_NN 0_CD ._. 01_CD )_) ._. Both_DT total_JJ cholesterol_NN and_CC triglycerides_NNS showed_VBD an_DT association_NN
        with_IN time_NN since_IN smoking_NN cessation_NN (_(
        p_NN =_SYM 0_CD ._. 03_CD for_IN both_DT )_) and_CC an_DT overall_JJ trend_NN from_IN current_JJ to_TO never_RB smokers_NNS in_IN
        fully_RB adjusted_VBN models_NNS ._.
        Lastly_NNP ,_, the_DT inflammatory_JJ markers_NNS were_VBD examined_VBN in_IN fully_RB adjusted_VBN models_NNS ._. C-_NNP reactive_JJ
        protein_NN continued_VBD to_TO show_VB abatement_NN of_IN the_DT acute_JJ phase_NN response_NN with_IN reduced_VBN smoking_NN
        intensity_NN and_CC increased_VBN time_NN since_IN cessation_NN despite_IN adjustment_NN for_IN covariates_NNS (_( Table_NNP 4_LS )_) ._.
        White_JJ blood_NN cell_NN count_NN and_CC albumin_NN were_VBD associated_VBN with_IN smoking_NN intensity_NN but_CC not_RB with_IN time_NN
        since_IN cessation_NN ._. All_DT positive_JJ acute_JJ phase_NN reactants_NNS showed_VBD an_DT associated_VBN decline_NN from_IN
        current_JJ to_TO former_JJ to_TO never_RB smokers_NNS in_IN fully_RB adjusted_VBN models_NNS (_(
        p_NN ≤_NN 0_CD ._. 01_CD )_) ;_: albumin_NN ,_, likewise_RB showed_VBD a_DT significant_JJ increase_NN (_(
        p_NN -_: trend_NN ≤_NN 0_CD ._. 01_CD )_) ._.
        Analyses_NNS using_VBG pack-years_JJ were_VBD also_RB done_VBN (_( not_RB shown_VBN )_) ;_: the_DT results_NNS were_VBD unchanged_JJ using_VBG
        this_DT measure_NN ._. Additionally_RB ,_, data_NNS were_VBD reanalyzed_JJ excluding_VBG those_DT individuals_NNS with_IN prevalent_JJ
        cardiovascular_JJ disease_NN (_( not_RB shown_VBN )_) ;_: results_NNS were_VBD again_RB unchanged_JJ and_CC measures_NNS of_IN
        association_NN were_VBD even_RB slightly_RB stronger_JJR ._. Overall_RB ,_, we_PRP observed_VBD the_DT following_JJ associations_NNS :_:
        (_( 1_LS )_) improvement_NN in_IN both_DT inflammatory_JJ markers_NNS and_CC traditional_JJ risk_NN factors_NNS with_IN decreased_VBD
        intensity_NN of_IN smoking_NN ,_, and_CC (_( 2_LS )_) improvement_NN in_IN inflammatory_JJ markers_NNS with_IN increased_VBN time_NN since_IN
        smoking_NN cessation_NN ._.
      
      
        Discussion_NNP
        In_IN this_DT cross-sectional_JJ population-based_JJ study_NN ,_, we_PRP were_VBD able_JJ to_TO demonstrate_VB dose_NN effects_NNS
        from_IN smoking_NN and_CC temporal_JJ effects_NNS from_IN cigarette_NN smoking_NN cessation_NN ._. The_DT NHANES_NNP III_NNP dataset_NN
        allowed_VBD us_PRP to_TO utilize_VB both_DT self-reported_JJ smoking_NN and_CC serum_NN cotinine_NN levels_NNS to_TO minimize_VB
        misclassification_NN error_NN ._. It_PRP also_RB allowed_VBD us_PRP to_TO control_VB for_IN a_DT wide_JJ range_NN of_IN confounders_NNS and_CC
        assess_VB consistency_NN across_IN measures_NNS by_IN analyzing_VBG four_CD acute_JJ phase_NN proteins_NNS and_CC several_JJ
        traditional_JJ risk_NN factors_NNS ._. By_IN examining_VBG both_DT traditional_JJ risk_NN factors_NNS and_CC inflammatory_JJ
        markers_NNS of_IN cardiovascular_JJ risk_NN ,_, this_DT study_NN contributes_VBZ to_TO the_DT literature_NN by_IN providing_VBG a_DT
        more_RBR complete_JJ analysis_NN with_IN regard_NN to_TO the_DT effects_NNS of_IN smoking_NN and_CC smoking_NN cessation_NN ._.
        It_PRP is_VBZ known_VBN that_IN after_IN smokers_NNS give_VBP up_RB smoking_NN ,_, their_PRP$ risk_NN of_IN mortality_NN and_CC future_JJ
        cardiac_JJ events_NNS declines_NNS [_NN 32_CD ,_, 39_CD ]_NN ,_, but_CC there_EX is_VBZ little_JJ data_NNS quantifying_VBG the_DT rate_NN of_IN risk_NN
        reduction_NN and_CC when_WRB ,_, or_CC even_RB whether_IN ,_, cardiovascular_JJ risk_NN for_IN former_JJ smokers_NNS reaches_VBZ that_IN of_IN
        never_RB smokers_NNS [_NN 12_CD ,_, 40_CD ,_, 41_CD ]_NN ._. We_PRP found_VBD that_IN the_DT smoking-associated_JJ inflammatory_JJ response_NN
        subsides_NNS within_IN 5_CD y_NN after_IN smoking_VBG cessation_NN ._. This_DT suggests_VBZ that_IN the_DT vascular_NN effects_NNS are_VBP
        reversible_JJ and_CC that_IN cardiovascular_JJ risk_NN subsides_NNS gradually_RB with_IN reduced_VBN exposure_NN ._. The_DT time_NN
        to_TO risk_VB factor_NN “ correction_NN” was_VBD longest_JJS with_IN C-_NNP reactive_JJ protein_NN ;_: only_RB one_CD traditional_JJ risk_NN
        factor—triglycerides—showed_JJ a_DT similar_JJ pattern_NN ._. Our_PRP$ findings_NNS are_VBP consistent_JJ with_IN prior_JJ
        studies_NNS ,_, suggesting_VBG that_IN the_DT full_JJ benefit_NN of_IN smoking_NN cessation_NN may_MD be_VB achieved_VBN gradually_RB
        [_NN 39_CD ,_, 42_CD ,_, 43_CD ]_NN ._.
        Our_PRP$ estimates_NNS of_IN the_DT time_NN to_TO risk_VB factor_NN “ correction_NN” are_VBP shorter_JJR than_IN those_DT for_IN the_DT
        decline_NN in_IN mortality_NN risk_NN and_CC risk_NN for_IN specific_JJ cardiac_JJ events_NNS reported_VBD in_IN some_DT prospective_JJ
        studies_NNS [_NN 42_CD ,_, 44_CD ]_NN ,_, but_CC on_IN par_NN with_IN those_DT in_IN other_JJ prospective_JJ [_NN 45_CD ]_NN ,_, case-control_JJ [_NN 46_CD ,_, 47_CD ]_NN ,_, and_CC
        cross-sectional_JJ [_NN 48_CD ]_NN studies_NNS ._. Discrepancies_NNS may_MD be_VB due_JJ to_TO smoking_NN recidivism_NN in_IN prospective_JJ
        studies_NNS ,_, where_WRB former_JJ smokers_NNS recommence_NN smoking_NN and_CC increase_VB their_PRP$ risk_NN ,_, such_JJ that_IN the_DT
        reported_VBN time_NN since_IN cessation_NN is_VBZ longer_RBR than_IN the_DT true_JJ time_NN ,_, or_CC due_JJ to_TO a_DT lag_NN between_IN changes_NNS
        in_IN cardiovascular_JJ risk_NN factors_NNS and_CC regression_NN of_IN disease_NN ._. Additionally_RB ,_, one_PRP would_MD expect_VB
        morbidity_NN risk_NN to_TO subside_NN first_RB ,_, since_IN mortality_NN is_VBZ a_DT more_RBR distant_JJ endpoint_NN ._. Prior_RB studies_VBZ
        also_RB did_VBD not_RB control_VB for_IN known_VBN cardiovascular_JJ risk_NN factors_NNS ,_, did_VBD not_RB use_VB serum_NN cotinine_NN
        levels_NNS ,_, did_VBD not_RB examine_VB the_DT associated_VBN change_NN in_IN inflammatory_JJ markers_NNS post-cessation_JJ ,_, or_CC
        grouped_VBN participants_NNS into_IN broad_JJ categories_NNS of_IN current_JJ ,_, former_JJ ,_, and_CC never_RB smokers_NNS ,_,
        increasing_VBG residual_JJ confounding_VBG while_IN failing_VBG to_TO explore_VB the_DT relative_JJ effects_NNS within_IN each_DT
        group_NN [_NN 9_CD ,_, 12_CD ,_, 49_CD ]_NN ._. Nevertheless_RB ,_, it_PRP remains_VBZ unclear_JJ whether_IN C-_NNP reactive_JJ protein_NN 's_POS ongoing_JJ
        decline_NN in_IN former_JJ smokers_NNS simply_RB indicates_VBZ a_DT prevalent_JJ underlying_VBG burden_NN of_IN atherosclerotic_JJ
        plaque_NN ,_, or_CC “ simmering_VBG” ongoing_JJ disease_NN processes_NNS ._. The_DT direct_JJ associations_NNS of_IN C-_NNP reactive_JJ
        protein_NN with_IN mortality_NN decrement_NN seen_VBN in_IN these_DT other_JJ studies—and_NN the_DT dose–response_NN seen_VBN in_IN
        our_PRP$ own_JJ study—suggest_NN the_DT latter_NN ._.
        Three_CD studies_NNS have_VBP systematically_RB examined_VBN inflammatory_JJ markers_NNS following_JJ smoking_NN :_: the_DT
        MONICA_NNP Study_NNP (_( Monitoring_NN Trends_NNP and_CC Determinants_NNP in_IN Cardiovascular_NNP Disease_NNP )_) [_NN 46_CD ]_NN ,_, the_DT
        Cardiovascular_NNP Health_NNP Study_NNP (_( CHS_NNP )_) [_NN 48_CD ]_NN ,_, and_CC the_DT Northwick_NNP Park_NNP Heart_NNP Study_NNP [_NN 45_CD ]_NN ._. The_DT
        Cardiovascular_NNP Health_NNP Study_NNP found_VBD no_DT association_NN between_IN inflammatory_JJ markers_NNS and_CC smoking_NN
        status_NN itself_PRP ,_, although_IN C-_NNP reactive_JJ protein_NN was_VBD strongly_RB related_VBN to_TO lifetime_NN smoking_NN
        exposure_NN as_IN measured_VBN by_IN pack-years_JJ ._. Our_PRP$ results_NNS ,_, while_IN based_VBN on_IN more_RBR complete_JJ modeling_NN ,_,
        support_NN findings_NNS from_IN the_DT Northwick_NNP Park_NNP Heart_NNP Study_NNP and_CC MONICA_NNP Study_NNP ,_, both_DT of_IN which_WDT found_VBD
        that_IN fibrinogen_NN levels_NNS (_( adjusted_VBN only_RB for_IN age_NN )_) reached_VBN normal_JJ levels_NNS within_IN 5_CD y_NN ._.
        Our_PRP$ study_NN supports_VBZ the_DT hypothesis_NNS that_IN cardiovascular_JJ risk_NN falls_VBZ with_IN inflammatory_JJ
        abatement_NN ,_, and_CC that_IN inflammatory_JJ markers_NNS are_VBP better_JJR indicators_NNS of_IN such_JJ risk_NN reduction_NN ._. In_IN
        this_DT analysis_NN ,_, triglycerides_NNS showed_VBD the_DT strongest_JJS dose-intensity_JJ and_CC temporal_JJ trends_NNS of_IN the_DT
        traditional_JJ cardiovascular_JJ risk_NN factors_NNS ._. This_DT is_VBZ both_DT consistent_JJ with_IN prior_JJ research_NN and_CC
        not_RB surprising_VBG since_IN the_DT strongest_JJS association_NN between_IN C-_NNP reactive_JJ protein_NN and_CC lipid_NN
        measures_NNS is_VBZ for_IN triglycerides_NNS ._. Despite_IN the_DT colinearity_NN ,_, the_DT inflammatory_JJ markers_NNS studied_VBN
        appear_VB to_TO have_VB a_DT much_RB clearer_JJR trend_NN and_CC longer_RBR lasting_JJ effect_NN after_IN smoking_VBG cessation_NN than_IN
        traditional_JJ risk_NN factors_NNS ._. This_DT would_MD suggest_VB their_PRP$ greater_JJR utility_NN in_IN being_VBG more_RBR accurate_JJ
        markers_NNS of_IN disease_NN ,_, particularly_RB given_VBN C-_NNP reactive_JJ protein_NN 's_POS increasingly_RB apparent_JJ role_NN in_IN
        the_DT pathogenesis_NNS of_IN atherosclerosis_NNS ._. Alternative_NNP explanations_NNS include_VBP (_( 1_LS )_) the_DT presence_NN of_IN
        multiple_JJ independent_JJ causal_NN pathways_NNS leading_VBG to_TO cardiovascular_JJ disease_NN and_CC (_( 2_LS )_) traditional_JJ
        risk_NN factors_NNS correlating_VBG more_RBR closely_RB with_IN mortality_NN than_IN morbidity_NN or_CC underlying_VBG
        pathophysiology_NN ._. The_DT relative_JJ value_NN of_IN novel_NN inflammatory_JJ markers_NNS versus_CC traditional_JJ risk_NN
        factors_NNS remains_NNS of_IN much_JJ debate_NN [_NN 50_CD ,_, 51_CD ]_NN ._.
        Limitations_NNPS of_IN this_DT study_NN include_VBP measurement_NN error_NN from_IN self-reporting_JJ ,_, residual_JJ
        confounding_VBG from_IN use_NN of_IN indicator_NN variables_NNS ,_, smoking_NN recidivism_NN ,_, lack_NN of_IN newer_JJR measures_NNS
        such_JJ as_IN interleukin-_NN 6_CD and_CC high-sensitivity_JJ C-_NNP reactive_JJ protein_NN [_NN 52_CD ]_NN ,_, and_CC lack_NN of_IN data_NNS on_IN
        secondhand_NN smoke_NN ._. Recent_JJ studies_NNS have_VBP suggested_VBN that_IN toxin_NN exposures_NNS from_IN secondhand_NN smoke_NN
        may_MD impact_VB the_DT biomarkers_NNS used_VBN in_IN this_DT study_NN [_NN 53_CD ,_, 54_CD ]_NN ._. We_PRP attempted_VBD to_TO adjust_VB for_IN bias_NN in_IN
        self-reporting_JJ and_CC secondhand_NN exposure_NN by_IN using_VBG serum_NN cotinine_NN levels_NNS ,_, but_CC residual_JJ
        confounding_VBG may_MD exist_VB ._. It_PRP has_VBZ also_RB been_VBN suggested_VBN that_IN circulating_VBG C-_NNP reactive_JJ protein_NN
        levels_NNS may_MD not_RB reflect_VB all_DT relevant_JJ inflammatory_JJ effectors_NNS ,_, owing_VBG to_TO post-transcriptional_JJ
        regulation_NN of_IN C-_NNP reactive_JJ protein_NN [_NN 22_CD ]_NN ._. We_PRP chose_VBD C-_NNP reactive_JJ protein_NN ,_, however_RB ,_, for_IN its_PRP$ clear_JJ
        role_NN in_IN the_DT inflammatory_JJ response_NN and_CC for_IN its_PRP$ increasing_VBG clinical_JJ relevance_NN ._. Lastly_NNP ,_, it_PRP is_VBZ
        noteworthy_JJ that_IN we_PRP are_VBP not_RB using_VBG a_DT linear_JJ scale_NN ,_, but_CC measures_NNS of_IN both_DT intensity_NN and_CC
        duration_NN ._. Time_NNP since_IN cessation_NN and_CC cigarettes_NNS per_IN day_NN are_VBP distinctly_RB different_JJ measures_NNS ,_,
        and_CC a_DT discontinuity_NN arises_VBZ at_IN cessation_NN ._.
        Further_RB research_NN should_MD explore_VB the_DT acute_JJ phase_NN response_NN in_IN the_DT months_NNS following_VBG smoking_NN
        cessation_NN [_NN 53_CD ,_, 55_CD –_NN 57_CD ]_NN ._. Time_NN intervals_NNS of_IN less_JJR than_IN a_DT year_NN since_IN cessation_NN have_VBP not_RB been_VBN
        assessed_VBN adequately_RB in_IN other_JJ studies_NNS nor_CC in_IN this_DT study_NN because_IN of_IN sample_NN size_NN limitations_NNS
        of_IN the_DT NHANES_NNP III_NNP data_NNS ._. Additionally_RB ,_, if_IN cardiovascular_JJ risk_NN subsides_NNS gradually_RB upon_IN
        smoking_NN cessation_NN ,_, do_VBP vessel_NN wall_NN damage_NN and_CC pro-aggregatory_JJ cascades_NNS all_DT completely_RB
        reverse_NN course_NN upon_IN cessation_NN ?_. Future_JJ research_NN should_MD continue_VB to_TO explore_VB the_DT relationship_NN
        between_IN the_DT inflammatory_JJ cascade_NN and_CC alterations_NNS in_IN the_DT vessel_NN wall_NN [_NN 7_CD ,_, 58_CD ]_NN ._.
        This_DT and_CC other_JJ similar_JJ studies_NNS suggest_VBP that_DT smoking_NN cessation_NN should_MD play_VB a_DT larger_JJR role_NN
        in_IN public_JJ policy_NN ._. Linked_NNP to_TO poverty_NN ,_, decreased_VBD productivity_NN ,_, and_CC premature_JJ death_NN ,_, tobacco_NN
        remains_VBZ the_DT second_JJ major_JJ cause_NN of_IN preventable_JJ death_NN in_IN the_DT world_NN and_CC fourth_JJ most_RBS common_JJ
        risk_NN factor_NN for_IN disease_NN worldwide_NN [_NN 59_CD ]_NN ._. While_IN tobacco_NN is_VBZ clearly_RB a_DT worldwide_NN concern_NN ,_,
        states_NNS and_CC localities_NNS are_VBP left_VBN responsible_JJ for_IN addressing_VBG tobacco_NN use_NN and_CC smoking_NN in_IN a_DT
        comprehensive_JJ manner_NN ._. Our_PRP$ results_NNS suggest_VBP that_IN policy-makers_NNS faced_VBN with_IN escalating_VBG
        health-care_NN costs_NNS should_MD look_VB to_TO smoking_NN cessation_NN as_IN an_DT opportunity_NN to_TO achieve_VB both_DT long-_NN
        and_CC short_JJ
        -_: term_NN health-care_NN cost_NN savings_NNS through_IN cardiovascular_JJ risk_NN reduction_NN
        [_NN 60_CD ]_NN ._. If_IN cardiovascular_JJ benefits_NNS are_VBP ,_, in_IN fact_NN ,_, readily_RB attainable_JJ ,_, there_EX exists_VBZ an_DT
        opportunity_NN for_IN short-term_JJ gain_NN from_IN smoking_NN cessation_NN ._. This_DT may_MD be_VB sufficient_JJ to_TO induce_VB
        policy_NN change_NN ._. Larger_NNP scale_NN action_NN is_VBZ also_RB needed_VBN ._. Arguments_NNP persist_VB in_IN the_DT developing_VBG
        world_NN regarding_VBG the_DT forced_VBN opening_NN of_IN tobacco_NN markets_NNS as_IN a_DT result_NN of_IN the_DT Global_NNP Agreements_NNP
        on_IN Tariffs_NNPS and_CC Trade_NNP ._. Guidance_NNP may_MD be_VB forthcoming_JJ ,_, however_RB ,_, from_IN the_DT World_NNP Health_NNP
        Organization_NNP Framework_NNP Convention_NNP on_IN Tobacco_NNP Control_NNP ,_, which_WDT began_VBD operation_NN in_IN February_NNP
        2005_CD as_IN an_DT international_JJ treaty_NN aimed_VBN at_IN controlling_VBG tobacco_NN packaging_NN ,_, marketing_NN ,_, and_CC use_NN
        [_NN 61_CD ]_NN ._. Over_IN 60_CD nation-states_JJ are_VBP currently_RB parties_VBZ to_TO the_DT Framework_NNP Convention_NNP on_IN Tobacco_NNP
        Control_NNP ,_, including_VBG many_JJ European_JJ nations_NNS and_CC Japan_NNP ,_, although_IN the_DT United_NNP States_NNPS has_VBZ yet_RB to_TO
        approve_VB this_DT treaty_NN ._. Opportunities_NNPS for_IN tobacco_NN control_NN remain_VB available_JJ ,_, and_CC it_PRP is_VBZ becoming_VBG
        increasingly_RB clear_JJ that_DT smoking_VBG cessation_NN models_NNS deserve_VBP high_JJ priority_NN both_DT in_IN research_NN and_CC
        in_IN any_DT preventive_JJ health_NN care_NN system_NN ._.
      
    
  
